health
protect
agenc
studi
number
peopl
test
hiv
sexual
health
clinic
return
diagnosi
report
reveal
number
infect
individu
uk
end
estim
approxim
individu
unawar
infect
fig
mani
patient
remain
anonym
sexual
health
clinic
therefor
imposs
trace
inform
test
result
obvious
sever
impact
risk
hiv
transmiss
shown
sever
studi
darnel
et
al
hivposit
individu
awar
infect
avoid
practic
associ
highrisk
hiv
transmiss
one
prioriti
area
unaid
framework
reduc
transmiss
hiv
test
hiv
point
care
may
increas
number
adult
will
take
test
result
produc
time
test
would
therefor
reduc
risk
transmiss
allow
antivir
treatment
start
point
care
test
poct
investig
carri
near
patient
side
rapid
immunochromatograph
flow
particl
agglutin
assay
provid
result
immedi
within
minut
depend
test
devic
small
volum
patient
sampl
requir
perform
test
often
drop
blood
finger
sampl
format
use
poct
vari
devic
serum
plasma
whole
blood
saliva
major
poct
devic
approv
diagnost
use
involv
hivrecombin
antigen
andor
synthet
peptid
bound
membran
poct
devic
sampl
appli
membran
antibodi
present
form
complex
membranebound
antigen
induc
colour
reaction
addit
detect
hiv
antibodi
new
fourthgener
poct
also
detect
presenc
hiv
antigen
antibodi
antigen
membran
bound
detect
antigen
sampl
test
reduc
time
diagnosi
hiv
infect
detect
studi
show
use
poct
detect
hiv
increas
rapidli
laboratori
clinic
set
especi
develop
countri
exampl
follow
introduct
poct
malawi
number
peopl
receiv
hiv
test
annual
rose
number
test
remain
receiv
result
increas
hiv
poct
often
perform
nonlaboratori
train
individu
result
test
interpret
user
subject
reli
heavili
user
expertis
knowledg
test
adequ
train
qualiti
assur
procedur
place
assay
ensur
reliabl
extern
qualiti
assess
eqa
import
role
qualiti
assur
measur
everi
laboratori
clinic
particip
eqa
scheme
allow
user
monitor
qualiti
assur
procedur
readili
identifi
remedi
problem
intern
qualiti
control
measur
demonstr
patient
profession
commit
particip
eqa
scheme
contribut
laboratori
accredit
statu
award
appropri
govern
bodi
instanc
clinic
patholog
accredit
although
particip
eqa
scheme
compulsori
sexual
health
clinic
laboratori
unless
wish
gain
accredit
bulletin
medicin
healthcar
product
regulatori
agenc
document
intern
organ
standard
iso
relat
point
care
test
en
iso
state
user
poct
particip
appropri
eqa
scheme
eqa
involv
analysi
simul
specimen
design
reflect
characterist
clinic
sampl
simul
specimen
known
undisclos
content
sent
regular
interv
often
monthli
quarterli
particip
laboratori
particip
test
sampl
use
routin
procedur
report
result
eqa
provid
result
particip
analys
report
produc
show
particip
result
anonym
result
particip
scheme
report
also
includ
cumul
assess
particip
perform
allow
monitor
perform
period
time
unit
kingdom
nation
extern
qualiti
assess
servic
uk
neqa
microbiolog
lead
extern
qualiti
assess
eqa
provid
uk
provid
eqa
scheme
disciplin
relat
microbiolog
diagnost
laboratori
across
uk
worldwid
time
studi
eqa
provid
uk
offer
profici
test
scheme
hiv
point
care
test
given
use
hiv
poct
rise
rapidli
uk
worldwid
studi
propos
eqa
hiv
poct
provid
benefici
ensur
qualiti
reliabl
result
patient
especi
primari
care
set
support
laboratori
avail
septemb
uk
neqa
microbiolog
publish
result
hiv
point
care
test
questionnair
sent
genito
urinari
medicin
clinic
across
questionnair
sought
inform
whether
poct
use
frequenc
use
assay
type
sampl
format
use
eg
whole
blood
serum
oral
fluid
etc
intent
project
develop
distribut
pilot
hiv
point
care
test
eqa
scheme
interest
particip
laboratori
clinic
set
purpos
variou
kit
avail
market
hiv
point
care
test
use
demonstr
perform
exist
uk
neqa
hiv
serolog
sampl
focu
detect
antihiv
antibodi
possibl
detect
hiv
antigen
fourthgener
poct
effect
variou
subtyp
hiv
serum
sampl
perform
hiv
poct
assay
also
determin
feedback
uk
neqa
questionnair
sent
sexual
health
clinic
across
uk
identifi
current
user
hiv
poct
devic
employ
select
commonli
use
hiv
poct
devic
includ
investig
name
determin
ab
third
gener
insti
test
oraquick
rapid
antibodi
test
addit
test
determin
agab
combo
fourthgener
poct
includ
test
becam
avail
spring
perform
kit
investig
use
two
differ
set
uk
neqa
hiv
serolog
specimen
plasma
eqa
provid
nh
blood
transplant
live
donor
donat
receiv
uk
neqa
provid
without
patient
identifi
eqa
materi
live
donor
exempt
human
tissu
act
ethic
approv
requir
first
set
specimen
previous
character
genscreen
ultra
eia
innolia
line
assay
determin
hiv
group
base
result
specimen
select
test
select
determin
hiv
strain
band
profil
reveal
line
assay
rang
differ
profil
select
nineteen
hivposit
specimen
previous
dilut
use
neg
sera
dilut
vari
one
specimen
dilut
addit
specimen
confirm
neg
hiv
antibodi
hepat
b
surfac
antigen
hepat
c
antibodi
also
includ
test
specimen
retest
use
genscreen
ultra
agab
eia
result
use
refer
poct
result
second
set
specimen
previous
character
molecular
method
subgroup
viral
load
establish
five
specimen
subgroup
b
c
g
select
test
poct
perform
across
subgroup
specimen
heat
inactiv
min
viral
inactiv
fulli
complet
ad
tween
specimen
test
accord
manufactur
instruct
poct
kit
reactiv
result
score
basi
colour
intens
strongest
weakest
addit
investig
perform
second
set
specimen
retest
dilut
specimen
dilut
use
serum
confirm
neg
hiv
antibodi
hepat
b
surfac
antigen
hepat
c
antibodi
poct
signal
produc
dilut
specimen
compar
initi
signal
produc
test
specimen
undilut
current
user
hiv
poct
sexual
health
clinic
well
particip
uk
neqa
hiv
serolog
scheme
use
hiv
poct
invit
particip
pilot
eqa
scheme
hiv
point
care
test
via
letter
wish
particip
ask
respond
within
given
time
respond
within
time
limit
contact
via
telephon
identifi
reason
respond
provid
anoth
opportun
particip
fortysix
invit
letter
sent
chose
particip
scheme
nh
laboratori
sexual
health
clinic
particip
sexual
health
clinic
given
uniqu
identifi
number
identifi
ensur
result
report
remain
confidenti
anonym
current
particip
hiv
serolog
scheme
alreadi
assign
uniqu
identifi
four
eqa
serolog
specimen
distribut
pilot
scheme
particip
along
repli
form
report
result
instruct
safeti
inform
also
includ
return
result
analys
determin
perform
specimen
kit
use
perform
poct
kit
investig
use
first
set
specimen
fulli
character
enzym
immunoassay
eia
line
assay
specimen
correctli
show
reactiv
result
antibodi
poct
howev
specimen
show
weak
reactiv
result
hiv
antibodi
insti
hiv
oraquick
rapid
antibodi
kit
includ
four
specimen
specimen
test
neg
hiv
antigen
result
valid
control
line
clearli
observ
test
accuraci
result
obtain
assur
retest
specimen
use
genscreen
eia
match
previou
character
result
obtain
outsid
refer
laboratori
variat
signal
strength
poct
depict
fig
typic
variat
observ
studi
specimen
differ
poct
determin
poct
produc
clear
reactiv
result
everi
specimen
signal
determin
test
grade
fig
insti
test
devic
exampl
signal
seen
specimen
signal
specimen
signal
specimen
oraquick
rapid
antibodi
devic
exampl
show
signal
strength
apart
specimen
signal
display
investig
oraquick
rapid
antibodi
insti
test
result
comparison
innolia
line
assay
result
show
correl
line
assay
band
intens
reactiv
signal
strength
oraquick
rapid
antibodi
devic
similar
find
report
studi
oconnel
et
al
individu
low
level
antibodi
yield
falseneg
result
oraquick
rapid
antibodi
devic
correl
made
insti
test
result
innolia
result
investig
effect
subtyp
poct
result
perform
use
second
set
specimen
fulli
character
molecular
method
subtyp
specimen
produc
clear
reactiv
signal
poct
effect
observ
due
differ
subtyp
interestingli
reactiv
signal
observ
overal
much
stronger
signal
observ
first
set
specimen
fig
anticip
differ
signal
strength
observ
may
due
dilut
specimen
addit
investig
perform
second
set
specimen
retest
dilut
result
compar
initi
signal
produc
test
specimen
undilut
tabl
littl
differ
observ
determin
test
signal
clear
whether
specimen
neat
dilut
expect
due
perform
test
throughout
studi
effect
signal
strength
observ
insti
oraquick
rapid
antibodi
test
result
decreas
case
tabl
howev
clear
correl
signal
strength
dilut
factor
could
made
order
select
suitabl
specimen
distribut
pilot
scheme
result
poct
investig
evalu
serolog
specimen
select
first
set
produc
strongest
reactiv
signal
across
poct
devic
base
evalu
three
serolog
specimen
two
one
select
addit
serolog
specimen
confirm
neg
hiv
select
uk
neqa
stock
also
includ
distribut
pilot
scheme
feedback
uk
neqa
hiv
poct
questionnair
identifi
user
hiv
poct
sexual
health
clinic
clinic
well
current
particip
uk
neqa
hiv
serolog
scheme
use
hiv
poct
invit
particip
pilot
scheme
overal
respons
receiv
set
result
return
two
set
result
pend
particip
await
test
kit
fig
four
eqa
serolog
specimen
distribut
pilot
scheme
particip
along
repli
form
report
result
return
result
analys
determin
perform
specimen
kit
use
popular
kit
use
determin
agab
determin
ab
insti
ab
fig
three
particip
chose
test
sampl
use
combin
kit
name
determin
hiv
ab
unigold
n
determin
hiv
immunocomb
ii
hiv
bispot
n
hiv
determin
insti
n
overal
perform
excel
pilot
scheme
particip
report
correct
result
one
particip
report
indetermin
result
specimen
use
insti
ab
test
one
particip
report
hiv
antigen
posit
neg
specimen
use
determin
agab
combo
test
fig
investig
perform
poct
use
first
set
hiv
serolog
specimen
reveal
poct
show
correct
result
reactiv
result
insti
oraquick
rapid
antibodi
kit
weak
case
could
lead
difficulti
interpret
whilst
determin
kit
produc
clear
reactiv
result
seem
case
dilut
specimen
effect
intens
reactiv
signal
observ
insti
oraquick
rapid
antibodi
result
although
clear
correl
dilut
factor
signal
intens
could
made
effect
dilut
sera
may
poct
result
taken
account
select
specimen
futur
distribut
investig
effect
variou
subtyp
poct
show
strong
reactiv
result
devic
regardless
subtyp
howev
limit
panel
subtyp
test
within
group
increas
immigr
introduc
greater
incid
circul
recombin
form
crf
nonb
subtyp
group
part
world
usual
studi
king
colleg
st
thoma
hospit
show
preval
newli
acquir
infect
nonb
subtyp
increas
uk
europ
individu
includ
studi
infect
nonb
subtyp
acquir
infect
pose
challeng
poct
devic
larg
base
subgroup
b
antigen
peptid
uk
neqa
microbiolog
provid
eqa
scheme
worldwid
includ
part
africa
preval
nonb
subgroup
higher
studi
assess
subtyp
aim
incorpor
current
circul
strain
futur
distribut
specimen
includ
studi
posit
hiv
antigen
anticip
use
determin
agab
combo
increas
time
studi
alreadi
employ
particip
recommend
materi
sourc
futur
investig
may
prove
difficult
sourc
antigenposit
materi
blood
would
need
donat
recent
infect
individu
seroconvers
occur
patient
progress
late
stage
aid
level
antigen
increas
antibodi
level
diminish
may
also
possibl
spike
exist
uk
neqa
specimen
antigen
recombin
antigen
commerci
avail
howev
may
also
prove
difficult
practic
antibodi
present
serum
sampl
would
form
complex
antigen
upon
addit
render
undetect
poct
particip
perform
pilot
scheme
excel
construct
feedback
receiv
particip
although
overal
lack
awar
eqa
scheme
within
sexual
health
clinic
role
scheme
set
becam
appar
case
clinic
never
encount
even
heard
eqa
unawar
type
assess
would
benefit
upon
explain
purpos
benefit
eqa
interest
shown
particip
clinic
number
rose
person
contact
clinic
timeconsum
process
prove
difficult
make
contact
appropri
peopl
especi
clinic
open
twice
week
case
contact
unawar
would
give
consent
particip
unwil
help
often
telephon
messag
followup
email
left
unansw
accept
lack
awar
eqa
main
reason
low
number
particip
sexual
health
clinic
howev
correspond
chose
particip
also
highlight
reason
particip
cost
implic
concern
clinic
oper
chariti
even
though
pilot
free
charg
take
account
cost
kit
involv
test
clinic
interest
scheme
particip
due
lack
staff
time
certain
clinic
oper
day
week
felt
eqa
anoth
burden
heavi
workload
minor
case
gener
lack
interest
eqa
encount
clinic
question
felt
intern
qualiti
assur
measur
suffici
futur
pilot
studi
recommend
promot
scheme
carri
local
manag
level
would
import
target
higher
manag
level
primari
care
trust
chariti
organ
involv
sexual
health
terrenc
higgin
trust
british
associ
sexual
health
hiv
promot
benefit
eqa
make
awar
recommend
medicin
healthcar
product
regulatori
agenc
intern
organ
standard
need
eqa
scheme
may
develop
also
provid
qualiti
technic
train
term
point
care
infer
test
carri
patient
side
action
care
immedi
howev
wider
use
import
eqa
provid
identifi
user
poct
use
type
set
exampl
necessari
perform
test
laboratori
test
encount
set
sexual
health
clinic
develop
countri
charit
organ
visit
remot
villag
test
whole
popul
hospit
healthcar
set
case
accident
exposur
possibl
test
perform
due
eas
use
rather
point
care
rapid
test
often
case
patient
sampl
refer
laboratori
confirmatori
test
delay
result
patient
uk
recommend
hiv
poct
use
screen
mani
set
sir
liam
donaldson
uk
chief
medic
offic
professor
christin
beasley
uk
chief
nurs
offic
request
hiv
test
carri
healthcar
set
includ
gener
practic
hospit
emerg
depart
depart
within
hospit
hivposit
patient
unawar
infect
statu
may
present
diseas
common
aid
hiv
exampl
thorac
depart
case
pneumonia
encount
also
recommend
hiv
screen
use
rapid
assay
new
patient
taken
gp
surgeri
labour
ward
also
recommend
user
hiv
poct
order
screen
women
labour
yet
test
routin
antenat
appoint
research
ascertain
extent
hiv
poct
use
set
order
identifi
possibl
eqa
particip
current
time
cure
vaccin
hiv
prevent
transmiss
way
reduc
number
new
infect
hiv
remain
signific
threat
public
health
uk
worldwid
howev
earli
diagnosi
improv
use
point
care
test
togeth
effect
treatment
mean
affect
live
longer
decreas
risk
transmit
infect
studi
conclud
need
eqa
provid
test
integr
part
ensur
reliabl
result
qualiti
care
patient
ca
gain
bsc
hon
biomed
scienc
hope
embark
success
reward
career
diagnost
microbiolog
immedi
aspir
complet
ibm
specialist
portfolio
gain
msc
medic
microbiolog
